ClinicalTrials.gg
CompletedNCT01028924Updated May 7, 2012

Effects of Teduglutide on Cardiac Repolarisation and Conduction in Healthy Male and Female Volunteers

A Phase 1 interventional study of Teduglutide in Healthy, sponsored by Nycomed. Completed at 1 site in Germany. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2012-05-07.

Sponsored by Nycomed (part of Takeda) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.

Enrollment
4th of 20
72 · median 20
Started
2009
with 1 other
Phase 1
Only one
of the 20
Registered
5th of 20
by date
Lead sponsor
1 of 20
Nycomed

Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 4th largest by enrollment, is one of 2 that started in 2009, is the only one in phase 1, and was the 5th registered.

Short Bowel Syndrome

159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.

Browse Short Bowel Syndrome studies →

Open to participants now

1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About teduglutide

teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing teduglutide in Short Bowel Syndrome, or all of them as a file.
02

Study summary

The primary objective of this trial is to investigate if teduglutide has an effect on cardiac repolarisation (QT, QTc interval). Secondary objectives are the investigation of possible effects on heart rate and cardiac conduction (RR and PR intervals, QRS duration), pharmacokinetics and safety and tolerability in healthy subjects, and to determine the effect of the positive control, moxifloxacin, for sensitivity analysis. The trial will consist of a screening and a treatment phase of four treatment periods. There is a washout period of at least 7 days and 4 weeks at maximum between administrations. The expected total trial duration for the individual subject will be about 7 weeks (maximum 17) weeks.

03

Conditions studied

  • Healthy

Browse trials for

Keywords

  • Thorough QTc-Study
  • Short Bowel Syndrome
  • Cardiac safety
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Healthy male or female volunteers
  • Normal body weight ( within ≥18 and 29 kg/m2 (inclusive) and a body weight >50 kg (females) and >60 kg (males).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Teduglutide 5 mg

    Treatment A, subcutaneous injection

    Drug: Teduglutide

  • Experimental
    Teduglutide 20 mg

    Treatment B, subcutaneous injection

    Drug: Teduglutide

  • Placebo comparator
    Placebo

    subcutaneous injection

    Drug: Teduglutide

  • Active comparator
    Moxifloxacin

    400 mg, oral

    Drug: Teduglutide

Interventions

06

What researchers measure

Primary outcomes

  1. ECG measurement/assessment to determine the effect of a single dose of teduglutide on cardiac repolarisation (QT, QTc interval).

    Time frame: until 24 h post dose

Secondary outcomes

  1. ECG measurement/assessment to determine the effect of a single dose of a positive control, moxifloxacin, on cardiac repolarisation, heart rate, and conduction

    Time frame: until 24 h post dose

  2. ECG measurement/assessment to determine the effect of a single dose of teduglutide on heart rate and cardiac conduction (RR and PR intervals, QRS duration)

    Time frame: until 24 h post dose

  3. PK blood samples to investigate pharmacokinetics of teduglutide in plasma

    Time frame: until 24 h post dose

  4. PK blood samples to explore the concentration effect relationship on QT/QTc intervals

    Time frame: until 24 h post dose

  5. ECG measurement/assessment and PK blood samples to investigate safety and tolerability of teduglutide

    Time frame: within 14 days after trial medication administration

07

Study locations

1 site
  • Nycomed GmbH
    Konstanz, 78467, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Feb 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2009
First posted
Dec 9, 2009
Start
Nov 2009
Primary completionActual
Feb 2010
CompletionActual
Apr 2010
Last update
May 7, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01028924
Lead sponsor
Nycomed
First posted
Dec 9, 2009
Start date
Nov 2009
Primary completion
Feb 2010
Completion
Apr 2010
Last update
May 7, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teduglutide

Start the discussion